linjc16/ctgov huggingface dataset:
Forehead Lift Fixation

Study Overview
=================
Brief Summary
-----------------
To compare periosteum versus bone fixation in forehead lift.

Detailed Description
-----------------
Forehead lift method of fixation is variable and lots of different methods have been described with different rates of success. The comparison of to different techniques in a RCT has not been reported before. The objective is to compare periosteum versus bone fixation in forehead lift, in a randomized, blinded, controlled, split-face trial.

Official Title
-----------------
Periosteum Versus Bone for the Fixation of Forehead Lift: A Prospective, Randomized, Controlled, Split-Face Trial.

Conditions
-----------------
Forehead

Intervention / Treatment
-----------------
* Procedure: Periosteum
* Procedure: Bone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eye brow malposition Forehead wrinkles Exclusion Criteria: Previous surgery Forehead trauma or scar

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Periosteum | Procedure: Periosteum<br>* Periosteum fixation<br>|
| Experimental: 2<br>Bone | Procedure: Bone<br>* Bone tunnel fixation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eye brow position |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' satisfaction |  | 6 months | 
| Complications |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Plastic Surgery
Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection

Study Overview
=================
Brief Summary
-----------------
The purpose of the trial is to evaluate the effect of Djulis-Buckwheat drink on cardiovascular protection after ingesting for 8 weeks. In addition, the correlation between the supplement and the cardiovascular disease-related gene expression is evaluated. The results will be used for the application of functional products for cardiovascular protection. Ninety subjects (age 30 65) with Prehypertension or Hypertension stage 1 will be included and randomly allocated into 3 groups: Placebo, Djulis-Buckwheat and Buckwheat. The subjects will take sample (100 ml/day) for 8 weeks. Blood pressure will be measured on week 0, 1, 2, 4, 6 and 8. The blood biochemical parameters and gene expression analysis will be examined on week 2, 4, 6, 8 and 10 (the follow up).

Official Title
-----------------
Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection

Conditions
-----------------
Prehypertension, Hypertension Stage 1

Intervention / Treatment
-----------------
* Dietary Supplement: Placebo
* Dietary Supplement: Djulis-Buckwheat
* Dietary Supplement: Buckwheat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Systolic blood pressure 121-159 mmHg or Diastolic blood pressure 81-99 mmHg Age: 30-65 Exclusion Criteria: Have diagnosed and documented critical illness(NHI specification) Had emergency record or admission note in the past three months Not be pregnant or breast-feeding a child

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Djulis-Buckwheat & Placebo<br>Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks | Dietary Supplement: Placebo<br>* Ingest placebo drink 100ml/day for 8 weeks<br>Dietary Supplement: Djulis-Buckwheat<br>* Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks<br>|
| Active Comparator: Buckwheat & Placebo<br>Ingest Buckwheat or placebo drink 100ml/day for 8 weeks | Dietary Supplement: Placebo<br>* Ingest placebo drink 100ml/day for 8 weeks<br>Dietary Supplement: Buckwheat<br>* Ingest Buckwheat drink 100ml/day for 8 weeks<br>|
| Experimental: Djulis-Buckwheat & Buckwheat<br>Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks | Dietary Supplement: Djulis-Buckwheat<br>* Ingest Djulis-Buckwheat drink 100ml/day for 8 weeks<br>Dietary Supplement: Buckwheat<br>* Ingest Buckwheat drink 100ml/day for 8 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of blood pressure |  | Baseline, 1, 2, 4, 6, and 8 weeks |
Risk Factors for COVID-19 Mortality

Study Overview
=================
Brief Summary
-----------------
COVID-19 pandemic has deeply burdened hospitals all over the world. A two-stage disease has been hypothesized due to quick worsening of clinical status after 7-10 days from the beginning of first symptoms, generally flu-like symptoms. Predicting clinical worsening could help to address major efforts towards higher risk patients. During the last year most observational studies, generally retrospective, has been conducted, identifying some risk factors such as age, obesity, male gender, cardiovascular disease, COPD, diabetes etc. The study goal is to collect systematically a variegate amount of clinical, biometric, laboratory and radiological data from patients admitted to the Emergency Medicine Ward of Piacenza Hospital (Italy), in order to prospectively analyze what characteristics are associated to higher risk of mortality.

Official Title
-----------------
Risk Factors for COVID-19 Mortality: a Prospective Observational Study

Conditions
-----------------
COVID-19 Virus Infection, Population at Risk, Acute Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admission to the Emergency Medicine Ward from the Emergency Department of Piacenza Hospital (Italy) Confirmed COVID-19 diagnosis through molecular test obtained from nasal-pharyngeal swabs in the Emergency Department Age above 18 Exclusion Criteria: inability to obtain an informed consent due to neurological conditions. patient's refusal to sign the informed consent inability of researchers to recruit the patient in the first 24 hours from the admission.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate | Number of patients who die for any cause in the first 28 days after admission | 28 days after admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Need of invasive ventilation | Number of patients who need invasive ventilation in the first 15 days after admission | 15 days after admission |
Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

Study Overview
=================
Brief Summary
-----------------
Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.

Official Title
-----------------
A Radiomics Approach to Predict the Effect of Bevacizumab Plus Chemotherapy in Patients With Liver Metastases of Colorectal Cancer: A Prospective Multi-Centers Trial

Conditions
-----------------
Colon Cancer, Rectal Cancer, Liver Metastases

Intervention / Treatment
-----------------
* Drug: Bevacizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colorectal carcinoma confirmed by pathological result. Liver metastasis confirmed by imaging studies. Treatment of bevacizumab combined with chemotherapy chosen by MDT team. ECOG: 0-2. Normal laboratory studies including liver\renal\bone marrow functions. Expected lifespan more than 3 months. Exclusion Criteria: Previous treatment of colorectal cancer with liver metastasis. Diagnosed with other malignancies. Couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\pregnancy or lactation\chronic heart disease\unable to sustain further treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bevacizumab|bevacizumab combined with chemotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| estimated ORR |  | 6-8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| estimated PFS |  | 3 years | 
| estimated OS |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal cancer, liver metastasis, bevacizumab
To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets

Study Overview
=================
Brief Summary
-----------------
To demonstrate the relative bioavailability of Diclofenac Sodium 50 mg enteric-coated tablets.

Official Title
-----------------
A Relative Bioavailability Study of Diclofenac Sodium 50 mg Enteric-Coated Tablets

Conditions
-----------------
Inflammation

Intervention / Treatment
-----------------
* Drug: Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
* Drug: Voltaren 50 mg Tablets (Geigy Pharmaceuticals)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 41 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc) | Drug: Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)<br> <br> |
| Active Comparator: 2<br>Voltaren 50 mg Tablets (Geigy Pharmaceuticals) | Drug: Voltaren 50 mg Tablets (Geigy Pharmaceuticals)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 17 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anti-inflammatory
Management and Short Term Outcome of Traumatic Wounds in the Emergency Department

Study Overview
=================
Brief Summary
-----------------
Identify the risk factors for complications as well as study the evolution of wounds sutured in the emergency room towards complications such as superinfections, necrosis, disunity of the stitches linked to inadequate initial care.

Detailed Description
-----------------
All traumatic injuries should be considered contaminated upon presentation to the emergency room. This is why the main objective of this study was to describe the attitude of patients towards their wounds, to identify the risk factors for complications as well as to study the evolution of sutured wounds in the emergency room towards complications such as superinfections, necrosis, disunity of stitches linked to inadequate initial treatment. This is a prospective, observational, monocentric study carried out in the emergency services of the Fattouma Bourguiba hospital in Monastir.

Official Title
-----------------
Management and Short Term Outcome of Traumatic Wounds in the Emergency Department

Conditions
-----------------
Wound Heal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who presented to the ambulatory emergency circuit of the EPS Fattouma Bourguiba Monastir having as main reason for consultation an acute suturable wound. Exclusion Criteria: Wounds requiring surgical treatment Septic wounds Chronic lesions Vascular wounds Patients who did not consent to the protocol.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evolution of the wound and the healing period. | After discharge from ED patients were called back in order to know information about the Suture complications(infection, release of stitches, hematoma, etc.) | day 10 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
wounds, superinfections, stitches
Grape Juice and Dermatitis in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This study aimed to investigate the effect of grape juice on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT). 50 eligible BC patients will randomly assign to consume 100 gr of grape juice per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.

Detailed Description
-----------------
Dietary intake of patients will be examined by expert dietitians at baseline and end of RT using the average of three-day 24-hour recalls. Weight (kg), body fat percentage, skeletal muscle percentage and visceral fat level will be measured using the OMRON Body Composition Monitor and Scale.

Official Title
-----------------
The Effect of Grape Juice Consumption on Radiotherapy-induced Dermatitis in Breast Cancer - A Pilot Study

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Dietary Supplement: grape juice
* Other: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with Brest Cancer undergoing adjutant Radiation therapy Exclusion Criteria: previous history of RT, MRM, concomitant presence of two or more malignant tumors metastasis to other areas allergy or intolerance to tahini skin diseases and wounds severe liver and renal disease autoimmune diseases pregnant and lactating women those who treated with hypo fraction RT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: grape juice<br>100 g of grape juice daily | Dietary Supplement: grape juice<br>* grape juice<br>|
| Placebo Comparator: control<br>no dietary intervention | Other: control<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| severity of dermatitis | Change from Baseline severity at 4 weeks. The radiation dermatitis will be assessed according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales | 4 weeks |
The Effect of White Sweet Potato Meal Replacement on Weight Control of the Obesity

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to use white-skinned sweet potato as the main material for weight control for overweight and obesity, the non-communicable diseases (cardiovascular diseases, cancers, chronic respiratory diseases and diabetes) are also included. All high quality sweet potato are provided by CAES in Taiwan to produce special nutrient food and health food that to do functional study in Shih Chien University and Taipei Medical University. In this study, the investigators will recruit overweight and obesity subjects that divide into white sweet potato group (experimental group) and no intervention group (control group) by using randomized, parallel and open clinical study in sixty days.

Detailed Description
-----------------
All subjects will be evaluated the body weight and clinical nutrition assessment such as postural measurement, urine test and blood biomarker examination.

Official Title
-----------------
Office of Human Research, Taipei Medical University

Conditions
-----------------
Overweight

Intervention / Treatment
-----------------
* Dietary Supplement: White sweet potato diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 24≦ BMI≦30 Exclusion Criteria: Pregnant and lactating women Patients within six months after surgery Mental illness or depression Suffering from cancer, ulcers, acute respiratory infections, dialysis, acute hepatitis and other diseases Those who have taken additional nutritional supplements habit

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control Group<br>Normal diet with 1500 2000 kcal | Dietary Supplement: White sweet potato diet<br>* The diet were supplied 516 kcal daily<br>|
| Experimental: Treatment Group<br>White sweet potato diet with 1500 2000 kcal | Dietary Supplement: White sweet potato diet<br>* The diet were supplied 516 kcal daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight After Intervention | Body weight change after 60 days intervention | 60 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Fat After Intervention | Body fat change after 60 days intervention | 60 days |
Clopidogrel Efficacy and Acute Coronary Syndromes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare clopidogrel effectiveness between severe hemodynamically unstable versus stable patients with acute myocardial infarction.

Detailed Description
-----------------
Clopidogrel exists in oral form only. As a prodrug, it has to be metabolized to the active form by cytochrome system in the liver. Both facts could lead to lower efficacy of the drug in hemodynamically unstable patients, where splanchnic and liver hypoperfusion is present. We hypothesised that clopidogrel efficacy is insufficient in patients with acute myocardial infarction and severe hemodynamic instability. Therefore we would like to compare the effect of clopidogrel in unstable STEMI patients on mechanical ventilation with stable STEMI patients.

Official Title
-----------------
The Comparison of Clopidogrel Efficacy in Patients With Acute Myocardial Infarction and Severe Hemodynamic Instability to Patients With Hemodynamically Uncomplicated Myocardial Infarction

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for unstable group: acute STEMI mechanical ventilation the need for catecholamine support. Inclusion Criteria for stable group: acute myocardial infarction Exclusion Criteria for any: previous treatment with clopidogrel clopidogrel administration during transport by ambulance known intolerance to clopidogrel history of thrombocytopenia (<150,000 platelets/ml) pre-existing liver disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Unstable<br>Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support | |
| Stable<br>Patients with myocardial infarction hemodynamically completely (Killip I)stable. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lower efficacy of clopidogrel determined by VASP measurement |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Higher frequency of stent thrombosis in the unstable group |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
platelet, VASP, clopidogrel, cardiogenic shock, myocardial infarction, percutaneous coronary intervention